OptiBiotix (OPTI) has this morning announced FY16 results in line with our expectations with early revenues of £0.3m, adj. LBT of £1.2m and adj. LPS of 1.3p. Significant commercial progress this year sees OPTI developing from a R&D company into a product company with a wide suite of products across multiple potential indications. Considerable commercial development has been achieved since our initiation note (24 Jan 2017) which includes the upcoming LP-LDL launch at Vitafoods
25 Apr 2017
FY16 results in line with expectations
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY16 results in line with expectations
OptiBiotix Health PLC (OPTI:LON) | 18.0 0 0.0% | Mkt Cap: 17.6m
- Published:
25 Apr 2017 -
Author:
Mark Brewer | Cavendish Research -
Pages:
12
OptiBiotix (OPTI) has this morning announced FY16 results in line with our expectations with early revenues of £0.3m, adj. LBT of £1.2m and adj. LPS of 1.3p. Significant commercial progress this year sees OPTI developing from a R&D company into a product company with a wide suite of products across multiple potential indications. Considerable commercial development has been achieved since our initiation note (24 Jan 2017) which includes the upcoming LP-LDL launch at Vitafoods